Current and conventional mental health therapy regimens are not a one-size-fits-all approach and are not effective for many people. Psychedelic medicine, particularly ketamine-assisted psychotherapy, has been showing promise as a highly-effective and fast-acting treatment option for treatment-resistant mental health conditions. With the safe and intentional use of consciousness-altering experiences supported by health professionals in the right set and setting, many people have found rapid and long-lasting results and are moving through barriers that were previously holding them back.
Field Trip Health is a specialty behavioral health company, dedicated to providing evidence-based, medically-supervised, ketamine-assisted psychotherapy (KAP) to clients experiencing persistent symptoms of depression, anxiety, and trauma. With a network of outpatient mental health centers across North America, Field Trip Health’s services focus on creating an environment of safety, self-empowerment, and collaboration to promote sustained therapeutic relief.
Dr. Michael Verbora (Medical Director, [email protected]) will discuss the current evidence and ongoing clinical work that Field Trip Health is facilitating, using psychedelic medicine to treat treatment-resistant mental health conditions — such as depression, anxiety, PTSD, and others considered on a case-by-case basis. This webinar is moderated by Conrad Page (Associate Director of Growth).
To learn more, we invite you to visit our website at www.fieldtriphealth.com. You’re also welcome to download our whitepaper at fieldtriphealth.com/whitepaper and follow us on your favourite social channels as @fieldtriphealth.